(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(0.37%) $78.40
(0.51%) $2.15
(0.43%) $2 318.50
(1.62%) $27.12
(-0.27%) $962.70
(0.01%) $0.929
(-0.06%) $10.87
(-0.01%) $0.797
(0.00%) $91.45
2 days till quarter result
(bmo 2024-05-08)
Expected move: +/- 8.17%
@ $4.90
Utstedt: 14 feb 2024 @ 21:50
Avkastning: -37.28%
Forrige signal: feb 14 - 19:56
Forrige signal:
Avkastning: 2.30 %
Live Chart Being Loaded With Signals
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer...
Stats | |
---|---|
Dagens volum | 1.34M |
Gjennomsnittsvolum | 2.26M |
Markedsverdi | 524.12M |
EPS | $0 ( 2024-05-01 ) |
Neste inntjeningsdato | ( $-0.390 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.470 |
ATR14 | $0.00600 (0.20%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-22 | Moore Timothy L. | Sell | 17 360 | Common Stock |
2024-03-14 | Chang David D | Sell | 53 393 | Common Stock |
2024-01-30 | Parker Geoffrey M. | Buy | 190 | Common Stock |
2024-01-25 | Moore Timothy L. | Buy | 341 515 | Stock Option (Right to buy) |
2024-01-25 | Moore Timothy L. | Buy | 96 600 | Common Stock |
INSIDER POWER |
---|
93.40 |
Last 94 transactions |
Buy: 32 219 312 | Sell: 32 079 170 |
Volum Korrelasjon
Allogene Therapeutics Inc Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
HEPA | 0.96 |
ULCC | 0.955 |
JBLU | 0.953 |
RIDE | 0.953 |
NGM | 0.953 |
TCMD | 0.952 |
IMBI | 0.952 |
FNCH | 0.951 |
VCNX | 0.95 |
ALLR | 0.95 |
10 Mest negative korrelasjoner | |
---|---|
SKYA | -0.962 |
LEGA | -0.957 |
BRIV | -0.955 |
ADAL | -0.953 |
TBSAU | -0.951 |
TBSA | -0.95 |
CRZN | -0.949 |
LDHA | -0.949 |
FTPA | -0.949 |
AGGR | -0.949 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Allogene Therapeutics Inc Korrelasjon - Valuta/Råvare
Allogene Therapeutics Inc Økonomi
Annual | 2023 |
Omsetning: | $95 000.00 |
Bruttogevinst: | $-242.82M (-255 598.95 %) |
EPS: | $-2.09 |
FY | 2023 |
Omsetning: | $95 000.00 |
Bruttogevinst: | $-242.82M (-255 598.95 %) |
EPS: | $-2.09 |
FY | 2022 |
Omsetning: | $243 000 |
Bruttogevinst: | $-16.49M (-6 783.95 %) |
EPS: | $-2.30 |
FY | 2021 |
Omsetning: | $38.49M |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-2.14 |
Financial Reports:
No articles found.
Allogene Therapeutics Inc
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.